Clinical Trial Update: Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for a CAR-T therapy targeting relapsed/refractory hematological malignancies, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancy

Drugs mentioned

• CAR-T therapy (Chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Shanxi Bethune Hospital | Conditions: Hematological Malignancy | Phase 2, Phase 3 | Status: UNKNOWN